



# Business Development & Funding in Life Science Research

<b>1. Introduction &amp; Purpose</b>	<b>1</b>
1.1 Position of Life Science Research	1
1.2 Integration of the “Omics” with Empirical Science	12
1.3 Focus for Life Science Research	17
1.4 Technologies & Analysis	21
<b>2. Business Structure</b>	<b>28</b>
2.1 Research Segments	28
2.2 Target Markets & Development Costs	35
2.3 Reagents, Equipment & Services Markets	47
2.4 Trends & Issues (Biopharma, Diagnostics, Medical Devices, etc)	53
<b>3. Commercial Development of Component Supply Vs Biotech. Products</b>	<b>65</b>
3.1 Segmentation by Application	65
3.2 Company Segmentation by Type	68
3.2.1 Reagent Supply Companies	69
3.2.2 Equipment & Systems Supply Companies	70
3.2.3 BioInformatics Companies	71
3.2.4 Life Science Research Services Companies	73
3.2.5 BioPharmaceutical Product Development Companies	74
3.2.6 Diagnostic Product Development Companies	76
3.2.7 Medical Devices & Other Biotechnology Companies	79
3.3 Commercial Development and Funding Requirements	81
3.4 Profiles of Funding Users & Review of Biotech Clusters	85
3.4.1 General Review of Users & Biotech Clusters	85
3.4.2 Life Science Research Customer Profiles	86
3.4.3 Pharmaceutical R&D Customer Profiles	89
3.4.4 Biotechnology Clusters	92
<b>4. Sources of Biotechnology Funding &amp; Quantification</b>	<b>124</b>
4.1 Introduction to Funding Sources	124
4.2 Government Sources	125
4.2.1 North America	125
4.2.2 Europe	1
4.2.3 Asia & Pacific Rim (including Japan & India)	176
4.3 Agency Sources (EU, WHO, UN, etc)	189
4.4 Venture Capital Sources	193
4.5 Private Investment Sources	200

4.6 Business to Business Investments & Alliances	202
4.7 Technology Transfer Support	208
4.8 Regional Quantification (North America, Europe, Japan, Other Asia)	209
<b>5. Business Models &amp; Dynamics</b>	<b>213</b>
5.1 Investment Priorities & Needs	213
5.2 Applications of Funding for Reagents, Equipment, Services, etc	220
5.3 Dynamics of Funding Supply	228
5.4 Key Trends & Regulatory Influences	235
5.5 Business Models & Impact of Changes in Funding	239
5.6 Current & Future Market Investment Dynamics	243
<b>6. Future Developments &amp; Business Opportunities</b>	<b>244</b>
6.1 Technology Developments	244
6.2 Segment Developments	248
6.3 Regional Developments	250
6.4 Regulatory & Political Developments	252
6.5 Strategic Options & Business Opportunities	256
6.6 Life Science Research Funding & Investment Changes	259
<b>7. Conclusion</b>	<b>264</b>
7.1 Business Overview	264
7.2 Overall Life Science Market Dynamics	268
7.3 Life Science Research Funding	271
7.4 Life Science Products Sales Revenue, 2005	275

## FIGURES

<b>1. Introduction &amp; Purpose</b>	<b>1</b>
Figure 1. Life Sciences Bioactivity Cascade	3
Figure 2. Financial Investment Perspective for Life Science Research, 2003	6
Figure 3. Biotechnology Industry Comparison of USA versus UK, 2002	8
Figure 4. Genomics & Proteomics Linkage	13
Figure 5. Technology & Analysis Shifts	14
Figure 6. Bioinformatics, Genomics & Proteomics and Drug Discovery Links	16
Figure 7. Application Areas for Life Science Research Reagents, Europe 1992 & 2002	18
Figure 8. Drug Discovery Processes & Life Science Research Technologies	20
Figure 9. S-Curve Model for Life Science Research Technologies	22
Figure 10. Pharma Industry Pressures & Escape Routes	24
Figure 11. New Life Science Industry Paradigm	25
Figure 12. Relative Share Performance, 1998 in USA	26
Figure 13. Costs to Market and Benchmark Success Levels	27
<b>2. Business Structure</b>	<b>28</b>
Figure 14. Life Science Research Market Segment Distribution, 2003	29
Figure 15. General Market Segment Uses for Life Science Products	33
Figure 16. Summary of Regional Clusters of Biotechnology Companies, Europe	34
Figure 17. Summary of Regional Clusters of Biotechnology Companies, USA	34
Figure 18. Biotechnology Revenues & Investment by Region, 2002	36
Figure 19. European Biotechnology Company Distribution by Country, 2002	37
Figure 20. Pharmaceutical Drug Development – Attrition Rates	44
Figure 21. Pharmaceutical Drug Development – Attrition Rate Costs	44
Figure 22. Technology & Drug Discovery Linkages	46
Figure 23. Life Science Research Product Categories – Global Market Figures, 2003 & 2007	48
Figure 24. Life Science Research Product Categories – Share & Growth, 2003 & 2007	49
Figure 25. Life Science Research Regional Markets – Share & Growth, 2003 & 2007	49
Figure 26. Life Science Research Products – Regional Market Figures, 2003	51
Figure 27. European Life Science Research Products – Overall Country Distribution, 2003	52
Figure 28. Healthcare Applications of Life Science Research Products	58
Figure 29. Non – Pharmaceutical Applications of Life Science Research Products	59
Figure 30. New Pharmaceutical Industry Paradigm	62
Figure 31. New Life Science Industry Paradigm	64

### 3. Commercial Development of Component Supply Vs Biotech. Products 65

Figure 32. Application Areas for Life Science Research Reagents, Europe 1992 & 2003	67
Figure 33. Biotechnology Average Deal Structures from 1993 to 2002	75
Figure 34. Pharma & Biopharma Comparative R&D Spend, 2002	75
Figure 35. Costs to Market and Benchmark Success Levels for Diagnostics & Pharma, 2002	78
Figure 36. Medical Device Product Groups, 2003	79
Figure 37. Clusters in United States of America, USA	93 - 99
Figure 38. Clusters in United Kingdom	100 - 104
Figure 39. Clusters in Ireland & Northern Ireland	105 - 106
Figure 40. Clusters in Germany	107 - 112
Figure 41. Clusters in France	113 - 115
Figure 42. Clusters in Sweden	116 - 117
Figure 43. Clusters in Finland	117
Figure 44. Clusters in Switzerland	118
Figure 45. Clusters in The Netherlands	119 - 122
Figure 46. Other Clusters	123

### 4. Sources of Biotechnology Funding & Quantification 124

Figure 47. NIH Funding History in USA, 2002 - 2004	126
Figure 48. Life Science Research Funding in USA, 2002 versus 2003	128
Figure 49. Funding Status in USA, 2003	129
Figure 50. Funding Status in Canada, 2003	131
Figure 51. Competitive Government Funding Schemes in UK, 2003	136
Figure 52. Funding Status in United Kingdom, 2003	138
Figure 53. Funding Status in Germany, 2003	142
Figure 54. Funding Status in France, 2003	146
Figure 55. Funding Status in Italy, 2003	148
Figure 56. Funding Status in Switzerland, 2003	151
Figure 57. Funding Status in Portugal, 2003	154
Figure 58. Funding Status for Scanbalt Region of Northern Europe, 2003	156
Figure 59. Funding Status in Finland, 2003	158
Figure 60. Funding Status in Sweden, 2003	160
Figure 61. Funding Status in The Netherlands, 2003	164
Figure 62. Funding Status in Belgium, 2003	166
Figure 63. Funding Status in Ireland, 2003	168
Figure 64. Funding Status in The Czech Republic, 2003	171
Figure 65. Funding Status in Poland, 2003	173
Figure 66. Funding Status in Israel, 2003	175
Figure 67. Projected Japanese Biotechnology Sector Markets, 2010	176
Figure 68. Comparative Biotechnology Patent Filings by Applications, 1990 - 1998	177
Figure 69. Funding Status in China, 2003	179
Figure 70. Funding Status in Taiwan, 2003	181
Figure 71. Funding Status in India, 2003	188
Figure 72. Venture Capital Business Intentions for, 2003	194
Figure 73. Venture Capital Business Preferences, 2003	195
Figure 74. Funding Implications of Economic Changes, 2003	196
Figure 75. Major VC Groups Active in Europe & Funds Available, 2002	197
Figure 76. Sample of Venture Funding Investment in Life Science, 2003	198
Figure 77. Key Selection Criteria for Venture Funding Investments, 2003	199
Figure 78. Risk and Deal Levels in Drug Discovery Alliances, 2003	202
Figure 79. Actions for Survival or Growth in Alliances	203
Figure 80. Defining Consequences for Partners in an Alliance	204
Figure 81. Reasons for Failed Alliances, 2003	204
Figure 82. BioPharma Deal Value by Product Stage, 1998 - 2002	206
Figure 83. Life Science Regional Funding Overview by Source of Investment	211

### 5. Business Models & Dynamics 213

Figure 84. Corporate Investment Options & Alliances, 2003	214
Figure 85. Cluster Basis of Competition Analysis - Example, 2003	219
Figure 86. Segment Basis of Competition Element Weighting - Life Science Research, 2003	225
Figure 87. Comparison of Government & Total Investment in Life Science Research, 2003	229
Figure 88. Records Required by Predicate Rules for CFR Part 11, 2003	238
Figure 89. Records Subject to 21 CFR Part 11 & Technical Controls for Compliance, 2003	238
Figure 90. Business Development Using Different Sources of Funds	242

<b>6. Future Developments &amp; Business Opportunities</b>	<b>244</b>
Figure 91. Examples of New Technology Developments in Life Science Research, 2003	245
Figure 92. Positions of Alliance Partners	260
Figure 93. Goals and Options for Alliance Partnerships	261
Figure 94. Different Importance of Funding or Investment to Alliance Partners	262
<b>7. Conclusion</b>	<b>264</b>
Figure 95. S-Curve Technology Development – General Dynamics	265
Figure 96. S-Curve Model for Reagents & Arrays, 2003	266
Figure 97. S-Curve Model for Equipment & Consumables, 2003	267
Figure 98. Life Science Research Funding Sources, Global 2003	271
Figure 99. Projected Life Science Research Funding Sources, Global 2005	273
Figure 100. Investment by Region and Source Comparisons, 2003 - 2005	274
Figure 101. Life Science Product Categories – 2003 versus 2007	276

Currency conversions always prove difficult in comparing global markets.

The focus in this Report has been to use the US Dollar (\$US) and Euro (€) effectively at an exchange rate of 1:1.

In relation to the pound Sterling (£) the conversion factor has been taken to be: \$ 1.6/£ 1

and for Japan the Yen was taken to be: Y 171.2/£/\$ 1.6.

Local currencies have been quoted and converted on this basis although when quoted from a reference source the appropriate conversion as quoted at the time is given.